Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

Next Previous
Trial Profile

A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZR-MD-001 (Primary)
  • Indications Dry eyes; Meibomian gland dysfunction
  • Focus Therapeutic Use
  • Sponsors Azura Ophthalmics

Most Recent Events

  • 03 Mar 2021 Topline results from the phase II program comprising of four phase 2 studies that evaluated the safety and efficacy of AZR-MD-001 (n=95), presented in an Azura Ophthalmics media release.
  • 07 Jan 2021 Status changed from not yet recruiting to completed.
  • 19 May 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top